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Abstract 
Background: Multiple sclerosis (MS) can be difficult to differentiate from other 
demyelinating diseases, notably Neuromyelitis Optica Spectrum Disorder (NMOSD). 
We previously showed that NMOSD is distinguished from MS by plasma complement 
biomarkers. 
 
Objective: Here we measure cerebrospinal fluid (CSF) complement proteins in MS, 
NMOSD, and clinically isolated syndrome (CIS), a neurological episode that may 
presage MS, to test whether these distinguish NMOSD from MS and CIS. Materials 
and methods: CSF (53 MS, 17 CIS, 11 NMOSD, 35 controls) was obtained, 
complement proteins (C4, C3, C5, C9, C1, C1q, Factor B (FB)) regulators (Factor I 
(FI), Factor H (FH), FH-Related Proteins 1, 2 and 5 (FHR125), C1 Inhibitor (C1INH), 
Properdin), and activation 
products (terminal complement complex (TCC), iC3b) were quantified by ELISA and 
results expressed relative to CSF total protein (μg/mg). 
 
Results: Compared to control CSF: I) levels of C4, C1INH and Properdin were 
elevated in MS; II) TCC, iC3b, FI and FHR125 were increased in CIS; III) all 
complement biomarkers except TCC, FHR125, Properdin and C5 were higher in 
NMOSD CSF. A statistical model comprising six analytes (C3, C9, FB, C1q, FI, 
Properdin) plus age/gender optimally differentiated MS from NMOSD. 
 
 
Introduction  
 
Multiple sclerosis (MS) is a chronic, immune-mediated, degenerative disease of the 
central nervous system (CNS), causing a wide range of symptoms including problems 
with movement, balance and vision. Other related inflammatory demyelinating 
diseases with overlapping features include Neuromyelitis Optica Spectrum Disorders 
(NMOSD) where demyelination affects predominantly the optic nerves and spinal cord 
resulting in loss of vision and spinal symptoms, and Clinically Isolated Syndrome 
(CIS), a transient first clinical episode with MS-like symptoms which may or may not 
be an early sign of MS. Because of the similarity of symptoms in the early phase of 
the three conditions, diagnosis and subsequent management can be difficult and so 
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there is an unmet need for biomarkers that enable early diagnosis and differentiation. 
Autoantibodies against the water channel aquaporin 4 (AQP4-Ab) are highly specific 
for NMOSD patients1-4; however, AQP4-Ab are absent in up to 40% of all NMOSD 
patients fulfilling the clinical criteria.5 These AQP4-Ab negative NMOSD patients can 
present with symptoms also encountered in MS and CIS, and correct diagnosis 
remains challenging. We and others have shown that complement activation drives 
pathology in both NMOSD and MS6-17, with evidence from immunohistochemistry6,13-
14,16,18,23 as well as studies measuring complement proteins in cerebrospinal fluid 
(CSF) and plasma/serum7,8,10-12,17,19,20. In our previous study of plasma complement 
biomarkers20 we found that several complement proteins and activation products were 
higher in NMOSD compared to MS or controls and a model comprising C1 inhibitor 
(C1INH) and terminal complement complex (TCC) distinguished NMOSD from MS 
(area under the curve (AUC): 0.98), while C1INH and C5 distinguished NMOSD from 
controls (AUC: 0.94). In the current study, we have built on the published work by 
investigating an expanded set of complement biomarkers, including complement 
proteins (C4, C3, C5, C9, C1, C1q, Factor B (FB)), regulators (Factor I (FI), Factor H 
(FH), Factor H Related Proteins 1, 2 and 5 (FHR125), C1INH, Properdin), and 
activation products (TCC, iC3b) in CSF with the aim of identifying informative markers 
that may help to differentiate NMOSD, MS and CIS. Measurement of CSF levels of 
complement analytes may not only contribute to differential diagnosis in demyelination 
but also aid stratification and help define pathogenesis. 
 
 
MATERIALS AND METHODS 
Samples 
CSF samples (n = 136) were obtained from the Welsh Neuroscience Research Tissue 
Bank in November 2016. Diagnosis at time of sample requisition was used to 
categorise as this diagnosis, which had emerged after a mean of 4.3 years of follow-
up, was regarded to be more reliable that the provisional diagnosis made at the time 
of CSF sampling. Diagnoses made at time of sample requisition, according to 
contemporary diagnostic criteria, were: 53 MS, 17 CIS, 11 NMOSD and 55 non-
inflammatory disease controls. Of note, because the samples were accessed in 2016, 
the CIS classification was based on the criteria current at that time; post-hoc we re-
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assessed the CIS group using the 2017 criteria and only one of the 17 was differently 
classified (as MS) by these criteria. Relevant demographic, clinical and routine 
laboratory data are summarised in Table 1.  
CSF red cell and white cell count, albumin and total protein were measured on freshly 
harvested samples and the presence of oligoclonal bands or anti-aquaporin-4 
antibodies assessed where appropriate to the putative diagnosis. Samples were then 
centrifuged (2000g/10mins) to remove cells and debris within 30 minutes of collection 
before being aliquoted and frozen at –80°C until use. Serum was collected at the same 
time as the CSF sample, measurement of serum albumin and total protein levels were 
assessed where appropriate to the putative diagnosis. Ethical approval for the study 
was obtained from the Research Ethics Committee for Wales (Ref 09/ MRE09/35).  
 
Immunoassays  
Complement analytes (n = 13) were selected for this study guided by reference to 
previous studies of complement biomarkers in MS and availability of reagents.  The 
concentrations of these 13 analytes: C3, C4, C5, C9, FB, FH, FI, FHR125 (measures 
FH-related proteins 1, 2 and 5), Properdin, C1INH, C1q, iC3b and TCC, were 
measured using established in-house ELISAs (Table 2). The available volumes of 
collected CSF varied between 0.2–0.5 ml, stored at -80°C. Nunc Maxisorp (VWR, UK) 
plates were coated with afﬁnity-purified capture antibody overnight at 4°C, wells 
washed 1 x with phosphate-buffered saline 0.1% Tween20 (Sigma Aldrich, Germany) 
(PBS-T) and blocked for 1 hour at room temperature (RT) with 1% bovine serum 
albumin (BSA) in PBS-T. After 3 washes puriﬁed protein standards or serum samples, 
optimally diluted in 0.1% BSA in PBS-T, were added to wells in duplicate and 
incubated for 1.5 hours at 37°C. Different sample dilutions were used for different 
assays (Table 2). Wells were washed 3 x with PBS-T then incubated (1 hour) at RT 
with detection antibody (either unlabelled or labelled in-house using horseradish 
peroxidase (HRP; EZ-Link Plus Activated Peroxidase Kit, ThermoFisher Scientific, 
UK) and washed 3 x with PBS-T. For assays using unlabelled detection antibodies, 
HRP-labelled secondary antibody (anti-mouse or anti-rabbit IgG as appropriate, 
Jackson ImmunoResearch, USA) was added to wells, incubated and washed as 
above. Signals were detected using o-Phenylenediamine dihydrochloride (OPD; 
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SIGMAFAST™, Sigma-Aldrich, Germany) and absorbance (492nm) was measured. 
Standards were included on each plate and samples from controls and patients were 
randomly assigned to eliminate assay bias. A nonlinear regression model was used to 
ﬁt standard curves generated by ELISA. Total protein concentration (µg/mg) was 
automatically calculated by reference to the standard curve using GraphPad Prism. 
Detection limits, working ranges and assay performance were determined as 
described20 using CSF from 35 controls. In order to correct for differing degrees of 
blood-brain barrier impairment, all analytes were expressed relative to CSF total 
protein concentration (µg/mg), measured at the time of analysis using the micro-BCA 
Protein Assay Kit (ThermoFisher Scientific, UK). 
 
Statistics 
Mann-Whitney tests were used to test significance of differences between the control 
group and each of the other three groups; MS, CIS and NMOSD. Sparse Partial Least 
Squares Discriminant Analysis (sPLS-DA) was used to select sets of variables that 
best separated the sample groups. The complement biomarkers that were the most 
strongly associated with diagnosis where combined into one model; Receiver–
Operating Characteristics (ROC) curves were constructed for the model, and the area 
under the curve (AUC) for the final model was calculated and compared to that for 
individual biomarkers. AUC was used to define the predictive power of the biomarker 
set that compromised the model. Any biomarkers that were not significant in the model 
were excluded from the analysis. All analyses were conducted using R software, 
version 3.2.3, including the packages ‘dunn.test’, ‘corrplot’, ‘FactoMineR’ and 
‘mixOmics’.  
 
RESULTS 
CSF levels of complement proteins are altered in demyelination  
All complement proteins were quantified by ELISA and expressed relative to CSF total 
protein concentration (µg/mg) measured using the micro-BCA assay, (Table 3, Figure 
1). Compared to controls: i) CSF levels of C4, C1Inh and Properdin were significantly 
elevated in MS CSF; ii) TCC, iC3b, FI and FHR125 were significantly increased in CSF 
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from CIS patients; iii) all tested complement biomarkers except TCC, Properdin, 
FHR125 and C5 were significantly higher in NMOSD CSF. Of note, the complement 
activation products iC3b and TCC were not detectable in the majority of the disease 
and control CSF samples (below the detection limit: Control, TCC = 97% / iC3b = 77%; 
MS, TCC = 89% / iC3b = 68%; NMOSD, TCC = 91% / iC3b = 27%; CIS, TCC = 76% 
/ iC3b = 41%); these were therefore not used in the final models. It is, however, 
interesting to note that detectable levels of iC3b were much more frequent in CIS and 
NMOSD groups compared to control and MS groups. We performed subgroup 
analyses in MS, NMOSD and CIS. There were no significant differences in analyte 
levels between OCB+ and OCB- MS samples except for a higher C3 level in the OCB- 
subgroup; comparison of AQP4-positive and AQP4-negative NMO samples showed 
significantly higher levels of iC3b, C3, C5, FI and the FHR proteins in the antibody-
positive samples. Patients designated CIS at the time of sample requisition were 
divided based on whether in the current diagnosis (24-30 months later) they had or 
had not converted to MS; of the analytes measured, only FI levels were significantly 
different between these subgroups, higher in convertors (Table 3).  
 
Sparse Partial Least Squares Discriminant Analysis (sPLS-DA) discriminates 
between NMOSD, MS and CIS groups. 
The principal component analyses correspond to the sets of complement biomarkers 
that contribute most to the statistical model (Figure 2A, B). The first component (PC1) 
discriminates NMOSD from MS and CIS; the most contributing analytes, with the 
highest loadings, are C9, iC3b, C1INH and C1q. The second component (PC2) clearly 
discriminates between CIS and MS through two analytes; higher levels of FI (strongly 
positively correlated, 0.97) in the CIS group and lower levels of C5 (negatively 
correlated, -0.25) in MS. Most of the assays (8 out of 13) showed signiﬁcant 
differences between the Control and NMOSD groups, with higher levels in the NMOSD 
group (Figure 2 A-C).  
 
A statistical model comprising six CSF complement analytes optimally 
differentiates MS from NMOSD.  
7 
 
Receiver-Operating Characteristic (ROC) analyses showed no significant contribution 
of complement biomarkers over demographics (age + gender) for differentiating MS, 
NMOSD or CIS from Controls; however, complement biomarkers markedly improved 
differentiation of MS and NMOSD in ROC analysis (Figure 2D). The six most 
significant complement analytes based on p-value, C3, C9, FB, C1q, FI and Properdin, 
were combined in the model. The other seven analytes were removed from the model 
after testing as they did not significantly contribute. The model to differentiate NMOSD 
from MS had an AUC 0.81, considered highly predictive (Figure 2D).   
 
 
 
Discussion 
Sensitive and specific biomarkers are essential for diagnosis, prediction and 
stratification of neurological diseases. Differentiating the demyelinating diseases MS 
and NMOSD is a particular priority because presenting symptoms can be similar but 
therapies that are effective in MS can exacerbate NMOSD21. To date, the best 
NMOSD biomarkers are the associated autoantibodies (AQP4-Ab and MOG-Ab); 
these are highly specific22, however, a significant proportion (20 – 30%) of NMOSD 
cases are autoantibody-negative and these are difficult to distinguish from MS. The 
role of complement in pathogenesis of both MS and NMOSD is well accepted; 
however, its nature and magnitude remain unknown. Here we present an in-depth 
analysis of complement in CSF in NMOSD, MS and CIS. We measured complement 
components (C4, C3, C5, C9, C1, C1q, FB) regulators (FI, FH, FHR, C1INH, 
Properdin), and activation products (TCC, iC3b) to identify their capacity to 
differentiate these demyelinating diseases. Given the complex and variable 
immunopathogenesis of MS, NMOSD and CIS, the use of a combination of CSF 
analytes is much more likely to yield an informative biomarker of disease that 
differentiates between these three diseases than any single analyte.  
CSF levels of C4, C1INH and Properdin were significantly elevated in MS compared 
to controls (p < 0.05). Increased plasma levels of complement protein C4 and classical 
pathway regulator C1INH in MS plasma have been demonstrated previously12,20. Our 
study supports this finding; increased levels of CSF C4 and C1INH imply ongoing 
complement dysregulation that is both local and systemic. CSF Properdin was also 
significantly increased in MS, a finding that might contribute to the perpetuation of 
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complement activation in the CSF through properdin stabilization of alternative 
pathway C3 convertases.  
Although TCC and iC3b were not detectable in the majority of CSF samples with the 
assays used and so not further utilised in models, a surprising finding was that the 
proportion of CIS patients showing ongoing complement activation, evidenced by 
elevated levels of the activation markers iC3b and TCC, was significantly greater in 
comparison with controls (iC3b, 59% vs 23%; TCC, 24% vs 3%), suggesting that there 
was ongoing complement activation and dysregulation in the CSF in CIS. There were 
only 17 CIS samples in our study so this finding is preliminary; nevertheless, it does 
make the case for a larger study of complement activation markers in CIS to discover 
whether they aid diagnosis and/or help predict whether progression to MS will occur.  
The three disease groups were divided into subgroups based on OCB status for MS, 
AQP4 antibody-positivity for NMO and conversion to MS in the CIS group. Although 
the numbers in the subgroups were small, some significant differences were observed. 
The only significant difference between OCB+ and OCB- MS subgroups was a higher 
C3 level in the OCB-; this might suggest increased complement consumption in the 
OCB+ group. AQP4+ NMO samples showed significantly higher levels of multiple 
complement analytes, iC3b, C3, C5, FI and the FHR proteins compared to AQP4- 
samples; numbers in these subgroups were small (6 and 5) so these findings are 
preliminary. CIS cases that subsequently converted to MS had significantly higher FI 
levels compared to non-convertors; again, subgroup numbers were small (5 and 12) 
so findings should be treated with caution. The data make the case for a similar 
subgroup analyses in larger sample sets.   
 
The combination of multiple analyte measurements into a single statistical model can 
provide a powerful predictive test as we have previously shown for plasma markers of 
disease20. Here we have combined CSF complement biomarkers in a model to 
distinguish between NMOSD and MS. A model comprising a combination of six CSF 
complement biomarkers (C3, C4, C5, C9, FH, FHR, and C1INH) plus demographics 
(age and gender) was capable of distinguishing these diseases with good predictive 
power (ROC analysis; AUC = 0.81; Figure 2D). Partial least squares analysis (sPLS-
DA) enabled the three disease groups to be distinguished (Figure 2A-C). In our 
previous study of plasma complement biomarkers, we showed that a statistical model 
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including just two plasma analytes, TCC and C1INH, differentiated NMOSD from MS 
with a predictive power (AUC) of 0.9820. We reasoned that the marked differences in 
plasma biomarkers between the groups were a reflection of differences in blood-brain 
barrier (BBB) integrity; the BBB leak in NMOSD allowing complement activation 
products to spill over from brain to blood. We anticipated that CSF complement 
biomarkers would be much more similar between the diseases, and indeed, that is 
what we show here. Nevertheless, the majority of measured analytes were 
significantly higher in NMOSD CSF compared to MS or controls, suggesting greater 
local complement dysregulation in NMOSD. Improved understanding of the roles of 
complement in demyelinating diseases may help not only in differential diagnosis but 
also in designing strategies for using anti-complement therapeutics to suppress local 
complement activation within the CNS to reduce disease severity. This approach could 
be particularly useful in patients with NMOSD where current therapies are of limited 
benefit.  In line with this proposition, a complement therapeutic, the C5-blocking 
antibody eculizumab, was recently FDA-approved for therapy of AQP4 positive 
NMOSD (https://news.alexion.com/press-release/product-news/alexion-receives-fda-
approval-soliris-eculizumab-treatment-adults-neuromy). 
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FIGURE LEGENDS 
 
Figure 1: Complement protein levels in CSF samples. Box and whisker plots are 
shown for each analyte except TCC where most samples were negative. CSF levels 
of C4, C1Inh and Properdin were significantly elevated in MS; all tested complement 
biomarkers except FHR, Properdin and C5 were significantly higher in NMO CSF. In 
CIS CSF, iC3b, FI and FHR125 were increased compared to the controls (data 
presented in µg/mg for all analytes). p values are presented above connecting bars 
for all significant inter-group differences. Abbreviations: CIS, clinically isolated 
syndrome; MS, multiple sclerosis; NMOSD, neuromyelitis optica spectrum disorder.  
 
Figure 2: sPLS-DA and ROC analyses reveal clustering of cases and 
discriminatory power of individual and identified sets of analytes.  
A) sPLS-DA was used to select variables that best separate the different sample 
groups; correlations of the variables with the Principal Components (PC1, PC2) are 
shown. B) PC1 best discriminates NMOSD from the other conditions while PC2 best 
discriminates between CIS and MS. C) The circle plot shows that NMOSD is 
associated with increased levels of multiple analytes (C3, C4, C5, C9, FH, FHR, and 
C1INH) while CIS is associated with increased FI levels. D) ROC curves comparing 
the model which best differentiates NMOSD from MS (Red; C3, C9, FB, C1q, FI, 
Properdin) with demographics (Blue; age/gender) alone. The area under the curve 
(AUC) for the final model, used to define predictive power for distinguishing NMOSD 
from MS, was 0.81. Abbreviations: AUC, area under the curve; CIS, clinically isolated 
syndrome; MS, multiple sclerosis; NMOSD, neuromyelitis optica spectrum disorder; 
PC1, principal component 1; PC, principal component 2; ROC, Receiver-operating 
characteristic; sPLS-DA, sparse Partial Least Squares Discriminant Analysis. 
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Figure 2  
A)      B) 
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MS -0.05 -0.53 
NMOSD 0.82 0.04 
 
 
 
C)       D) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
P
C
 2
 
PC 1 
PC 1 
P
C
 2
 
15 
 
Table 1  
Diagnostic 
category at 
time of 
analysis˅ 
Clinically 
Isolated 
Syndrome 
(CIS) 
Multiple 
Sclerosis (MS) 
Neuromyelitis 
Optica 
Spectrum 
Disorder 
(NMOSD) 
Controls 
Number (n) 17 53 11 55 
Age at time of 
sampling˅˅ 
(mean (range) 
in years) 
41.5 (17-65) 42.9 (21-68) 48.1 (23-78) 35.7 (17-84) 
Sex (number; 
%  female) 
14 (82%) 37 (70%) 10 (91%) 42 (75%) 
Disease 
duration at the 
time of 
sampling˅˅ 
(mean (range) 
in years) 
2.1 (0-13.2) 
(n=16) 
6.2 (0-45.9) 
(n=48)  
9.4 (0-29.7) 
(n=8)  
n/a 
Disease 
subtype at 
time of 
sampling˅˅  
4 Optic neuritis 
6 Myelitis 
7 Other 
8 CIS 
31 RR 
3 SP 
10 PP 
6 AQP4 +, 
5 AQP4 -˅˅˅ 
35 IIH 
3 Non-
inflammatory 
myelopathy 
3 
Cerebrovascular  
2 Non-
inflammatory 
optic neuropathy 
8 Other 
5 Unknown 
EDSS score at 
time of 
sampling˅˅ 
0.0-3.5    14 
(82%) 
4.0-6.0    1 
(6%) 
6.5-8.5    0 
(0%) 
NR         2 
(12%) 
0.0-3.5   37 
(71%) 
4.0-6.0   9 
(17%) 
6.5-8.5   3 (6%) 
NR       3 (6%) 
0.0-3.5   0 (0%) 
4.0-6.0   1 (9%) 
6.5-8.5   6 
(55%) 
NR        4 (36%) 
n/a 
Oligoclonal 
band + 
2  OCB + 
15 OCB - 
41 OCB + 
12 OCB – 
1 OCB + 
10 OCB - 
n/a 
CSF total 
protein (mean 
(range) in g/L) 
0.45 (0.21 – 
1.42) 
(n=17) 
0.39 (0.22 – 
0.78) 
(n=52^) 
0.59 (0.19 – 
2.10) 
(n=10^) 
0.33 (0.17 – 
0.95) 
(n=53^) 
CSF cells:  
RBCs 
                   
WBCs 
67 (0-610) 
4 (0-40) 
(n=15^) 
470 (0-15736) 
2 (0-14) 
(n=51^) 
53 (0-330) 
2 (0-8) 
(n=11) 
244 (0-6398) 
1 (0-16) 
(n=54^) 
CSF/serum 
Albumin ratio 
(mean (range)) 
7.2 (2.2-26.6) 
(n=17) 
5.6 (2.5-13.0) 
(n=52) 
9.8 (2.5-35.1) 
(n=10) 
n/a 
Interval from 
CSF sampling 
to biomarker 
5.0 (1.8-9.4) 5.4 (1.6-9.4) 3.7 (1.9-5.8) 3.2 (1.5-9.3) 
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analysis (mean 
(range) in 
years) 
Relapse at the 
time of sample 
acquisition 
(number (%)) 
0 (0%) 2 (4%) 3 (27%) n/a 
Relapse within 
12 months 
prior to CSF 
sampling 
(number (%)) 
12 (71%) 29 (56%) 4 (36%) n/a 
 
Table 1: Clinical and demographic characteristics of the cohort. AQP4 aquaporin 4 
antibody, CIS clinically isolated syndrome, EDSS Expanded Disability Status Scale, 
IIH idiopathic intracranial hypotension, RR relapse-remitting, PP primary progressive, 
SP secondary progressive, NR not recorded. The other diagnoses recorded in controls 
were: stiff person syndrome, fibromyalgia, mitochondrial myopathy, cerebellar ataxia, 
degenerative spinal disease, migraine, autoimmune encephalitis, normal pressure 
hydrocephalus.  ˅At the time of sample requisition for biomarker analysis; ˅˅At the time 
of CSF collection; ˅˅˅Serum AQP4 antibodies were assessed at the time of CSF 
sampling in 5 patients and at various intervals between -26 and +23 months of CSF 
sampling in 6 patients. ^reduced numbers of samples for these measures because 
data was not recorded on some of the patients. 
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 Table 2 
 
Assay Capture Antibody Detection Antibody Standard 
Working Ranges 
(ng/ml) 
Sample Dilution 
1 C1q 
Monoclonal anti-Human C1q 
(WL02, Hycult) 
Biotinylated Monoclonal anti-
Human C1q (DJ01, Hycult)* 
C1q  
 
32-100 1 in 4 
2 C3 Rabbit anti-C3 Rabbit anti-C3-HRP 
C3 
(Comptech) 
23-1000 1 in 80 
3 C4 Goat anti-C4 Monoclonal anti-C4-HRP 
C4 
(Comptech) 
8-500 1 in 4 
4 C5 Rabbit anti-C5 Monoclonal anti-C5 (2D5)* 
C5  
 
32-1000 1 in 2 
5 Factor B Monoclonal anti-FB (JC1) 
Monoclonal anti-FB (MBI 5)-
HRP 
FB  
 
63-1000 1 in 4 
6 Factor H Monoclonal anti-FH (OX24) Monoclonal anti-FH (35H9)-HRP 
FH  
 
16-1000 1 in 8 
7 
C1 
Inhibitor 
Monoclonal anti Human C1 
Inhibitor 
Rabbit anti-C1inhibitor* 
C1 Inhibitor  
 
4-100 1 in 40 
8 Properdin 
Monoclonal anti-Properdin 
(1.1.1) 
Monoclonal anti-Properdin 
(12-14-2)-HRP 
Properdin 
(Comptech) 
7-100 n/a (neat used) 
9 FHR125 
Monoclonal anti-FHR125 
(MBL125) 
Rabbit anti-FH* 
FHR125  
 
4-250 1 in 8 
10 TCC 
Monoclonal anti-TCC (aE11, 
Hycult) 
Monoclonal anti-TCC (E2)-HRP 
TCC  
 
63-1000 n/a (neat used) 
11 iC3b Monoclonal clone 9 
Monoclonal bH6 (HM2168, 
Hycult)-HRP 
iC3b 
(Comptech) 
32-1000 1 in 80 
12 C9 Monoclonal B7 Rabbit anti C9* 
C9 
 
4-100 1 in 8 
13 FI Monoclonal 1C/11 Monoclonal 7D4-HRP 
FI  
(Comptech) 
63-1000 n/a (neat used) 
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Table 2: Conditions used in the ELISA assay kits. All antibodies and standards were produced in-house unless otherwise specified. 
Abbreviations: FB, Factor B; FH, Factor H; FHR125, Factor H Related Proteins 1, 2 and 5; FI, Factor I; HRP, horseradish peroxidase; 
TCC, terminal complement complex; Comptech, Complement Technology Inc. (https://www.complementtech.com/); Hycult, Hycult 
Biotech Com. (https://www.hycultbiotech.com/). *These assays also used species-specific HRP-labelled antibody or HRP-avidin 
(Jackson ImmunoResearch, USA) as appropriate to label the detection antibody. 
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Table 3 
 
Table 3: Patient clinical characteristics and mean concentrations of complement proteins in MS, NMOSD, CIS and control CSF. In 
sub-analysis, NMOSD AQP4 positive (NMOSD+) vs negative (NMOSD-) and MS OCB positive (OCB+) vs negative (OCB-) and CIS 
non-converted vs converted to MS patients were compared. p values (in brackets) are calculated using Mann–Whitney test to 
compare each of the three conditions with controls or the relevant subgroups with each other in the sub-analysis; significant 
Group 
Sample 
Number 
Age  
(Mean) 
Gender 
Female 
(%) 
TCC iC3b FB FH FHR125 FI Properdin C1INH C1q C3 C4 C5 C9 
µg/mg 
(P) 
µg/mg   
(P) 
µg/mg 
(P) 
µg/mg 
(P) 
µg/mg 
(P) 
µg/mg 
(P) 
µg/mg    
(P) 
µg/mg 
(P) 
µg/mg  
(P) 
µg/mg 
(P) 
µg/mg 
(P) 
µg/mg 
(P) 
µg/mg   
(P) 
MS 53 43 72 
0.009 
(0.129) 
0.027 
(0.247) 
0.880 
(0.276) 
0.942 
(0.196) 
0.364 
(0.054) 
0.017 
(0.573) 
0.033 
(0.453) 
0.415 
(0.027*) 
0.342 
(0.264) 
2.806 
(0.326) 
1.238 
(0.025*) 
0.072 
(0.088) 
0.213 
(0.358) 
NMOSD 11 49 82 
0.052 
(0.373) 
0.085 
(‹0.0001*) 
1.346 
(0.013*) 
1.344 
(0.019*) 
0.440 
(0.054) 
0.081 
(0.016*) 
0.037 
(0.437) 
0.536 
(0.003*) 
0.671 
(0.0002*) 
4.541 
(0.020*) 
1.529 
(0.005*) 
0.132 
(0.038*) 
0.395 
(‹0.0001*) 
CIS 17 42 88 
0.052 
(0.028*) 
0.044 
(0.005*) 
1.135 
(0.023*) 
0.982 
(0.255) 
0.506 
(0.002*) 
0.121 
(0.018*) 
0.039 
(0.293) 
0.462 
(0.038*) 
0.403 
(0.031*) 
3.842 
(0.061) 
1.249 
(0.073) 
0.044 
(0.430) 
0.273 
(0.040*) 
Control 35 31 80 0.002 0.012 0.793 0.840 0.286 0.023 0.029 0.352 0.315 2.545 1.03 0.052 0.190 
Sub-analysis 
MS OCB+ 41 42 76.2 0.005 0.024 1.078 1.156 0.418 0.084 0.036 0.495 0.422 3.244 1.537 0.075 0.244 
MS OCB- 12 46.9 66.7 
0.019 
(0.052) 
0.043 
(0.359) 
1.347 
(0.330) 
1.133 
(0.857) 
0.514 
(0.161) 
0.053 
(0.530) 
0.048 
(0.073) 
0.566 
(0.097) 
0.579 
(0.148) 
4.053 
(0.040*) 
1.461 
(0.515) 
0.108 
(0.081) 
0.328 
(0.065) 
NMOSD+ 6 57.4 100 0.010 0.141 2.131 1.670 0.531 0.272 0.042 0.661 0.010 5.683 1.691 0.162 0.602 
NMOSD- 5 37.9 60 
0  
(n/a) 
0.024 
(0.004**) 
1.111 
(0.151) 
1.154 
(0.080) 
0.355 
(0.026*) 
0.075 
(0.027*) 
0.029 
(0.114) 
0.535 
(0.052) 
0.666 
(0.447) 
3.126 
(0.010**) 
1.859 
(0.488) 
0.045 
(0.030*) 
0.333 
(0.082) 
CIS Non-
Converters 
12 38.9 76.9 0.006 0.050 1.571 1.003 0.496 0.151 0.029 0.476 0.592 3.259 1.472 0.062 0.296 
CIS 
Converters 
to MS 
5 47.6 80 
0.040 
(0.783) 
0.030 
(0.439) 
1.243 
(0.793) 
1.166 
(0.369) 
0.602 
(0.325) 
0.444 
(0.032*) 
0.046 
(0.264) 
0.563 
(0.085) 
0.404 
(0.533) 
4.681 
(0.167) 
1.320 
(0.537) 
0.031 
(0.078) 
0.322 
(0.422) 
20 
 
differences are indicated by asterisks: *, p < 0.05; **, p < 0.01. Abbreviations: CIS, clinically isolated syndrome; MS, multiple sclerosis; 
NMOSD, neuromyelitis optica spectrum disorder. 
